# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

FORM 6	5-K
--------	-----

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2019

Commission File Number: 001-38452

## MEREO BIOPHARMA GROUP PLC

(Translation of registrant's name into English)

4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Address of principal executive office)

Indicate by check mark whether the registrant files or wil	ll file annual reports u	nder cover of Form 20-F or Form 40-F.
	Form 20-F ⊠	Form 40-F □
Indicate by check mark if the registrant is submitting the	Form 6-K in paper as	permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the	Form 6-K in paper as	permitted by Regulation S-T Rule 101(b)(7):

#### Mereo BioPharma Group plc Holding(s) in Company

**London, July 8, 2019** - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, today provided a regulatory news service (RNS) notification of major holdings through the London Stock Exchange plc, a copy of which is provided below.

RNS Number : 8439E Mereo BioPharma Group plc

08 July 2019

#### TR-1: Standard form for notification of major holdings

**NOTIFICATION OF MAJOR HOLDINGS** (to be sent to the relevant issuer <u>and</u> to the FCA in Microsoft Word format if possible)<sup>i</sup>

	1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached <sup>ii</sup> :  Mereo Biopharma Group PLC					
1b. Please indicate if the	e issuer is a non-UK issuer (pl	ease mark with an "	X" if approp	priate)		
Non-UK issuer						
2. Reason for the notific	cation (please mark the appropr	riate box or boxes w	rith an "X")			
An acquisition or disposa	al of voting rights					
An acquisition or disposa	al of financial instruments					
An event changing the br	reakdown of voting rights					
Other (please specify)iii: No trading in the stock -	Other (please specify) <sup>iii</sup> : No trading in the stock - voting control interest over stock transferred to new manager				X	
3. Details of person sub	ject to the notification obligat	ion <sup>iv</sup>				
Name			Woodford	Investment Management Ltd		
City and country of registered office (if applicable) 9400		9400 Gars	ington Road, Oxford, OX4 2HN	I, United Kingdom		
4. Full name of shareho	<b>Ider(s)</b> (if different from 3.)v					
Name						
City and country of regis	tered office (if applicable)					
5. Date on which the th	5. Date on which the threshold was crossed or reached in the control of the contr					
6. Date on which issuer notified (DD/MM/YYYY): 08/07/2019						
7. Total positions of person(s) subject to the notification obligation						
	% of voting rights attached to shares (total of 8. A)			Total number of votin rights of issuervii	ıg	

Resulting situation on the date on which threshold was crossed or reached	27.56%	27.56%	97,959,622
Position of previous notification (if applicable)	30.46%	30.46%	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii				
A: Voting rights attach	ed to shares			
Class/type of shares	Number of voting rightsix		% of voting rights	
ISIN code (if possible)	<b>Direct</b> (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BZ4G2K23	26,999,540		27.56%	
SUBTOTAL 8. A	26,999,540		27.56%	

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))				
Type of financial instrument	Expiration date <sup>x</sup>	Exercise/ Conversion Period <sup>xi</sup>	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights
		SUBTOTAL 8. B 1		

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))					
Type of financial instrument	Expiration date <sup>x</sup>	Exercise/ Conversion Period xi	Physical or cash settlement <sup>xii</sup>	Number of voting rights	% of voting rights
			SUBTOTAL 8.B.2		

<b>9. Information in relation to the person subject to the notification obligation</b> (please mark the applicable box with an "X")				
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii				X
017	` '	<u> </u>		
		and/or the financial instruments are eff	ectively held starting with	
the ultimate controlling natural p	erson or legal entityxiv (please add ad	ditional rows as necessary)		
Name <sup>xv</sup>	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold	
Woodford Investment Management Ltd	27.56	0.00	27.56	

10. In case of proxy voting, please identify:	
Name of the proxy holder	
The number and % of voting rights held	
The date until which the voting rights will be held	

11. Additional informationxvi	

Place of completion	9400 Garsington Road, Oxford, OX4 2HN, United Kingdom
Date of completion	08/07/2019

Further Enquiries	
Mereo Denise Scots-Knight, Chief Executive Officer Richard Jones, Chief Financial Officer	+44 (0)333 023 7300
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker to Mereo ) Phil Davies Will Goode	+44 (0)20 7894 7000
RBC Capital Markets (Joint Broker to Mereo ) Rupert Walford Jamil Miah	+44 (0)20 7653 4000
FTI Consulting (Public Relations Adviser to Mereo ) Simon Conway Brett Pollard Ciara Martin	+44 (0)20 3727 1000
Burns McClellan (US Public Relations Adviser to Mereo ) Lisa Burns Steve Klass	+01 (0) 212 213 0006

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 8, 2019

### MEREO BIOPHARMA GROUP PLC

By: /s/ Charles Sermon

Name: Charles Sermon
Title: General Counsel